- University of California, Berkeley School of Law (J.D., 2010); Order of the Coif; Recipient of two American Jurisprudence Awards; Articles Editor, Ecology Law Quarterly; Research Assistant to Professor Robert. C. Berring, Jr.
- Yale College (B.A., with distinction, Chinese Language and Literature, 2002)
Irell In The News
Ian Washburn is a partner in the Los Angeles office of Irell & Manella LLP. Mr. Washburn specializes in intellectual property litigation and complex business litigation, and his practice also includes patent post-grant proceedings. He has represented clients in numerous federal courts as well as before the United States Patent and Trademark Office, the ICC International Court of Arbitration, and the Delaware Court of Chancery.
Mr. Washburn's experience spans a variety of industries, including the biomedical, pharmaceutical, semiconductor and semiconductor packaging, and computer networking industries, as well as universities. Mr. Washburn also advises companies during patent license negotiations and advises on technology development and commercialization.
Mr. Washburn earned his J.D. from the University of California, Berkeley School of Law, where he was admitted to the Order of the Coif. He earned his B.A., with distinction, in Chinese Language and Literature from Yale College. Prior to law school Mr. Washburn worked for an investment management firm in New York and lived in Beijing.
Representative litigation matters in which Mr. Washburn has served as counsel (client bolded) include:
- Shareholder Representative Services v. Gilead Sciences, Inc. (Del. Ch.), contract litigation related to whether Gilead owed a bonus payment under a merger agreement related to Gilead's cancer-fighting PI3K inhibitor Zydelig. Following a trial, the Delaware Court of Chancery issued a complete defense verdict, rejecting the plaintiff's claim for over $50 million in damages.
- MyMail, Inc. v. Conduit Ltd., Perion Network Ltd., et al. (E.D. Tex., PTAB), patent litigation and related inter partes review involving patents related to browser toolbar technology. The case settled shortly before oral hearing in the inter partes review.
- Genentech, Inc. v. The Trustees of the University of Pennsylvania (N.D. Cal.), patent litigation involving patent related to monocolonal antibody therapies. Penn asserted that the primary use of Genentech's blockbuster anticancer drug Herceptin infringes Penn's patent. The case settled shortly before trial.
- Tessera v. Amkor Technology (I.C.C., N.D. Cal., D. Del., Cal. Sup. Ct.), a series of arbitrations before a three-judge panel from the International Chamber of Commerce, and various satellite cases, involving royalties due under an agreement licensing both patented and unpatented semiconductor packaging technology.
- Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc. (PTAB), inter partes review involving patents related to methods of using rituximab, one of the highest-selling biologic treatments for cancer and rheumatoid arthritis. BI filed a Request for Adverse Judgment for Abandonment of the Contest in the two proceedings that were instituted, asking the PTAB to enter an adverse judgment against BI. The requests were not filed pursuant to any settlement between the parties and were granted by the PTAB.
- Tessera v. Powertech Technology Inc. (N.D. Cal.), licensing disputes involving royalties due under an agreement licensing both patented and unpatented semiconductor packaging technology.
- Tessera v. Sony (N.D. Cal.), licensing dispute involving royalties due under an agreement licensing both patented and unpatented semiconductor packaging technology.
- “From Camera Obscura To Camera Futura: How Patents Shaped Two Centuries of Photographic Innovation and Competition,” 98 J. Pat. & Trademark Off. Soc’y 406 (2016)
Bar & Court Admissions
- 2010, California
- U.S. District Court, Central and North Districts of California
- U.S. Court of Appeals, Ninth Circuit